The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases
In brief
GLP-1 agonists linked to fewer hospitalizations and surgeries in obese IBD patients
Over half of Crohn's disease and ulcerative colitis patients are overweight or obese, and excess visceral fat worsens outcomes. Early human data show that GLP-1 receptor agonist therapy is safe and associated with lower rates of IBD-related hospitalization and surgical intervention, especially in obese individuals, although its impact on disease activity remains uncertain. Ongoing trials will clarify its role as an adjunct treatment.
- Journal
- Inflammatory bowel diseases (Q1)
- Published
- 13 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Poonam Beniwal-Patel, Sami Samaan, Maria T Abreu, Parakkal Deepak, Andres J Yarur
- PMID
- 42593078
- DOI
- 10.1093/ibd/izag151
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 16 August 2026): GLP‑1 receptor agonists as adjunct in inflammatory bowel disease
Abstract
Obesity is increasingly prevalent among patients with inflammatory bowel diseases (IBD), with more than half of individuals with Crohns disease (CD) or ulcerative colitis (UC) classified as overweight or obese at diagnosis. Beyond body mass index (BMI), visceral adipose tissue (VAT) is emerging as a critical determinant of adverse IBD outcomes, including increased disease activity, reduced therapeutic response, higher surgical risk, and postoperative recurrence. Obesity and excess VAT also amplify cardiometabolic comorbidities commonly observed in IBD, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerotic cardiovascular disease (CVD), even in patients without traditional risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed obesity management and confer established CVD and metabolic benefits. Preclinical studies show that GLP-1 RAs reduce visceral adiposity, modulate gut microbiota, enhance intestinal barrier integrity, and attenuate proinflammatory signaling pathways relevant to IBD pathogenesis. Emerging human data suggest that therapy with GLP-1 RAs is safe in patients with IBD and is associated with lower rates of hospitalization and surgical risk, particularly among patients with obesity, although effects on disease activity remain unclear. Several ongoing randomized controlled trials are evaluating GLP-1 RAs as adjunctive therapy for IBD. Beyond intestinal inflammation, GLP-1 RAs may favorably impact IBD-associated comorbidities, including MASLD, CVD, neurologic disorders, chronic pain, and metabolic bone disease. Important considerations include gastrointestinal tolerability, procedural implications for endoscopy, and the risk of lean muscle mass loss, underscoring the need for multidisciplinary care. As obesity becomes increasingly common in IBD, GLP-1 RAs represent a promising therapeutic strategy warranting further prospective investigation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.